Santos 1Q Oil, Natural Gas Output Falls 7%
By David Winning
SYDNEY--Santos said its oil and natural gas production fell by 7% in its latest quarter, after its operations were disrupted by bad weather and planned maintenance.
Santos reported production of 21.8 million barrels of oil equivalent in the three months through March, down from 23.4 million BOE in the final three months of 2023. Sales volumes were 8% lower at 23.2 million BOE, contributing to a 6% drop in sales revenue to US$1.4 billion.
Still, Santos said its free cash flow from operations totaled US$692 million in the quarter and its gearing was below 20% when operating leases were excluded.
"It positions us well to fund shareholder returns, backfill and sustain our existing business, complete our major projects and grow our Santos Energy Solutions business," said Chief Executive Kevin Gallagher.
Santos reiterated on Thursday that it expects to produce between 84 million and 90 million barrels of oil equivalent this year, down from 91.7 million BOE in 2023. It has also forecast sales volumes of 87 million-93 million BOE, compared with 96.4 million BOE a year ago.
Write to David Winning at david.winning@wsj.com
(END) Dow Jones Newswires
April 17, 2024 19:25 ET (23:25 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks